SOT | Before treatment | After treatment | |||
---|---|---|---|---|---|
N | % | N | % | ||
Cinnarzine group (n = 9) | |||||
Condition 4 | Normal | 7 | 77.8% | 9 | 100.0% |
Abnormal | 2 | 22.2% | Zero | 0.0% | |
Condition 5 | Normal | 6 | 66.7% | 9 | 100.0% |
Abnormal | 3 | 33.3% | Zero | 0.0% | |
Condition 6 | Normal | 6 | 66.7% | 7 | 77.8% |
Abnormal | 3 | 33.3% | 2 | 22.2% | |
Composite Score | Normal | 7 | 77.8% | 9 | 100.0% |
Abnormal | 2 | 22.2% | Zero | 0.0% | |
Propranolol group (n = 11) | |||||
Condition 4 | Normal | 9 | 81.8% | 10 | 90.9% |
Abnormal | 2 | 18.2% | 1 | 9.1% | |
Condition 5 | Normal | 10 | 91.0% | 11 | 100.0% |
Abnormal | 1 | 9.0% | Zero | 0.0% | |
Condition 6 | Normal | 6 | 54.6% | 10 | 90.9% |
Abnormal | 5 | 45.4% | 1 | 9.1% | |
Composite Score | Normal | 9 | 81.8% | 11 | 100.0% |
Abnormal | 2 | 18.2% | Zero | 0.0% | |
Topiramate group (n = 11) | |||||
Condition 3 | Normal | 10 | 90.9% | 10 | 90.9% |
Abnormal | 1 | 9.1% | 1 | 9.1% | |
Condition 4 | Normal | 10 | 90.9% | 10 | 90.9% |
Abnormal | 1 | 9.1% | 1 | 9.1% | |
Condition 5 | Normal | 9 | 81.8% | 9 | 81.8% |
Abnormal | 2 | 18.2% | 2 | 18.2% | |
Condition 6 | Normal | 5 | 45.4% | 9 | 81.8% |
Abnormal | 6 | 54.6% | 2 | 18.2% | |
Composite score | Normal | 9 | 81.8% | 10 | 90.9% |
Abnormal | 2 | 18.2% | 1 | 9.1% |